Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
Nolan TM, Deliyannis G, Griffith M, Braat S, Allen LF, Audsley J, Chung AW, Ciula M, Gherardin NA, Giles ML, Gordon TP, Grimley SL, Horng L, Jackson DC, Juno JA, Kedzierska K, Kent SJ, Lewin SR, Littlejohn M, McQuilten HA, Mordant FL, Nguyen THO, Soo VP, Price B, Purcell DFJ, Ramanathan P, Redmond SJ, Rockman S, Ruan Z, Sasadeusz J, Simpson JA, Subbarao K, Fabb SA, Payne TJ, Takanashi A, Tan CW, Torresi J, Wang JJ, Wang LF, Al-Wassiti H, Wong CY, Zaloumis S, Pouton CW, Godfrey DI. Nolan TM, et al. EBioMedicine. 2023 Dec;98:104878. doi: 10.1016/j.ebiom.2023.104878. Epub 2023 Nov 27. EBioMedicine. 2023. PMID: 38016322 Free PMC article. Clinical Trial.
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G, Gherardin NA, Wong CY, Grimley SL, Cooney JP, Redmond SJ, Ellenberg P, Davidson KC, Mordant FL, Smith T, Gillard M, Lopez E, McAuley J, Tan CW, Wang JJ, Zeng W, Littlejohn M, Zhou R, Fuk-Woo Chan J, Chen ZW, Hartwig AE, Bowen R, Mackenzie JM, Vincan E, Torresi J, Kedzierska K, Pouton CW, Gordon TP, Wang LF, Kent SJ, Wheatley AK, Lewin SR, Subbarao K, Chung AW, Pellegrini M, Munro T, Nolan T, Rockman S, Jackson DC, Purcell DFJ, Godfrey DI. Deliyannis G, et al. EBioMedicine. 2023 Jun;92:104574. doi: 10.1016/j.ebiom.2023.104574. Epub 2023 May 4. EBioMedicine. 2023. PMID: 37148585 Free PMC article.
mRNA vaccines encoding membrane-anchored RBDs of SARS-CoV-2 mutants induce strong humoral responses and can overcome immune imprinting.
Al-Wassiti HA, Fabb SA, Grimley SL, Kochappan R, Ho JK, Wong CY, Tan CW, Payne TJ, Takanashi A, Lee CL, Mugan RS, Sicilia H, Teo SLY, McAuley J, Ellenberg P, Cooney JP, Davidson KC, Bowen R, Pellegrini M, Rockman S, Godfrey DI, Nolan TM, Wang LF, Deliyannis G, Purcell DFJ, Pouton CW. Al-Wassiti HA, et al. Among authors: nolan tm. Mol Ther Methods Clin Dev. 2024 Nov 15;32(4):101380. doi: 10.1016/j.omtm.2024.101380. eCollection 2024 Dec 12. Mol Ther Methods Clin Dev. 2024. PMID: 39687732 Free PMC article.
Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget.
Kapoor R, Standaert B, Pezalla EJ, Demarteau N, Sutton K, Tichy E, Bungey G, Arnetorp S, Bergenheim K, Darroch-Thompson D, Meeraus W, Okumura LM, Tiene de Carvalho Yokota R, Gani R, Nolan T. Kapoor R, et al. Vaccines (Basel). 2023 Feb 7;11(2):377. doi: 10.3390/vaccines11020377. Vaccines (Basel). 2023. PMID: 36851254 Free PMC article.
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Lancet Infect Dis. 2024 Dec 5:S1473-3099(24)00667-4. doi: 10.1016/S1473-3099(24)00667-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39647494
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study.
Nolan T, Bhusal C, Hoberman A, Llapur CJ, Voloshyna O, Fink E, Gentile A, Wallace G, Richmond PC, Domachowske JB, Mzolo T, Lattanzi M, Toneatto D; BOOST Study Group. Nolan T, et al. Clin Infect Dis. 2024 Dec 26:ciae622. doi: 10.1093/cid/ciae622. Online ahead of print. Clin Infect Dis. 2024. PMID: 39722560
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Nolan T, Bhusal C, Beran J, Bloch M, Cetin BS, Dinleyici EC, Dražan D, Kokko S, Koski S, Laajalahti O, Langley JM, Rämet M, Richmond PC, Silas P, Tapiero B, Tiong F, Tipton M, Ukkonen B, Ulukol B, Lattanzi M, Trapani M, Willemsen A, Toneatto D; QUINTET study group. Nolan T, et al. Open Forum Infect Dis. 2024 Oct 30;11(11):ofae638. doi: 10.1093/ofid/ofae638. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39582508 Free PMC article. Clinical Trial.
120 results